Ganglioside GM1 (porcine) ameliorates paclitaxel-induced neuropathy in rats

Journal of the Medical Association of Thailand

Volumn 92, Issue 1, 2009, Pages 50-57

  Chentanez, Vilai ^a   Thanomsridejchai, Natthapaninee ^a   Duangmardphon, Natthara ^a   Agthong, Sithiporn ^a   Kaewsema, Atitaya ^a   Huanmanop, Thanasil ^a   Maneesri, Supang ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Ganglioside; GM1; Neuropathy; Paclitaxel

Indexed keywords

CREMOPHOR; GANGLIOSIDE GM1; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; GUILLAIN BARRE SYNDROME; HEAT TOLERANCE; HISTOPATHOLOGY; HYPOALGESIA; MALE; MICROTUBULE; MOTOR NERVE CONDUCTION; NERVE FIBER DEGENERATION; NEUROPATHY; NONHUMAN; RAT; SCHWANN CELL; SCIATIC NERVE; TAIL; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; G(M1) GANGLIOSIDE; NEUROTOXICITY SYNDROMES; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RATS; RATS, WISTAR; SENSATION;

EID: 59649090465     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.
2. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9.
3. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005; 50: 355-74.
4. Schrijvers D, Vermorken JB. Taxanes in the treatment of head and neck cancer. Curr Opin Oncol 2005; 17: 218-24.
5. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A 1980; 77: 1561-5.
6. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999; 10: 947-59.
7. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249: 9-17.
8. Rowinsky EK, Eisenhauer EA, Chaudhry V Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993; 20: 1-15.
9. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8.
10. Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol 1997; 35: 47-53.
11. Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, et al. Taxol produces a predominantly sensory neuropathy. Neurology 1989; 39: 368-73.
12. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6: 489-94.
13. van Gerven JM, Moll JW, van den Bent MJ, Bontenbal M, van der Burg ME, Verweij J, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994; 30A: 1074-7.
14. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47: 115-8.
15. Authier N, Fialip J, Eschalier A, Coudore F. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci Lett 2000; 291: 73-6.
16. Cavaletti G, Tredici G Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 1995; 133: 64-72.
17. Cliffer KD, Siuciak JA, Carson SR, Radley HE, Park JS, Lewis DR, et al. Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 1998; 43: 46-55.
18. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001; 94: 293-304.
19. Hadjiconstantinou M, Neff NH. GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems. J Neurochem 1998; 70: 1335-45.
20. Ferrari G Anderson BL, Stephens RM, Kaplan DR, Greene LA. Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J Biol Chem 1995; 270: 3074-80.
21. Oliveira AL, Langone F. GM-1 ganglioside treatment reduces motoneuron death after ventral root avulsion in adult rats. Neurosci Lett 2000; 293: 131-4.
22. Goettl VM, Neff NH, Hadjiconstantinou M. Sciatic nerve axotomy in aged rats: response of motoneurons and the effect of GM1 ganglioside treatment. Brain Res 2003; 968: 44-53.
23. Bianchi R, Berti-Mattera LN, Fiori MG, Eichberg J. Correction of altered metabolic activities in sciatic nerves of streptozocin-induced diabetic rats. Effect of ganglioside treatment. Diabetes 1990; 39: 782-8.
24. Figliomeni B, Bacci B, Panozzo C, Fogarolo F, Triban C, Fiori MG. Experimental diabetic neuropathy. Effect of ganglioside treatment on axonal transport of cytoskeletal proteins. Diabetes 1992; 41: 866-71.
25. Chentanez V, Sanguanrungsirigul S, Panyasawad N. Effects of ganglioside on paclitaxel (Taxol) induced neuropathy in rats. J Med Assoc Thai 2003; 86: 449-56.
26. Boyle FM, Wheeler HR, Shenfield GM. Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate. J Neurooncol 1999; 41: 107-16.
27. Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 1995; 38: 218-24.
28. Nagai Y, Momoi T, Saito M, Mitsuzawa E, Ohtani S. Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci Lett 1976; 2: 107-11.
29. Roytta M, Raine CS. Taxol-induced neuropathy: chronic effects of local injection. J Neurocytol 1986; 15: 483-96.
30. Persohn E, Canta A, Schoepfer S, Traebert M, Mueller L, Gilardini A, et al. Morphological and morphometric analysis of paclitaxel and docetaxel- induced peripheral neuropathy in rats. Eur J Cancer 2005; 41: 1460-6.
31. Bachis A, Rabin SJ, Del Fiacco M, Mocchetti I. Gangliosides prevent excitotoxicity through activation of TrkB receptor. Neurotox Res 2002; 4: 225-34.
32. Ferrari G, Greene LA. Promotion of neuronal survival by GM1 ganglioside. Phenomenology and mechanism of action. Ann N Y Acad Sci 1998; 845: 263-73.
33. Rabin SJ, Bachis A, Mocchetti I. Gangliosides activate Trk receptors by inducing the release of neurotrophins. J Biol Chem 2002; 277: 49466-72.
34. Cuello AC, Garofalo L, Kenigsberg RL, Maysinger D. Gangliosides potentiate in vivo and in vitro effects of nerve growth factor on central cholinergic neurons. Proc Natl Acad Sci U S A 1989; 86: 2056-60.
35. Ferrari G, Batistatou A, Greene LA. Gangliosides rescue neuronal cells from death after trophic factor deprivation. J Neurosci 1993; 13: 1879-87.
36. Garofalo L, Cuello AC. Nerve growth factor and the monosialoganglioside GM1: analogous and different in vivo effects on biochemical, morphological, and behavioral parameters of adult cortically lesioned rats. Exp Neurol 1994; 125: 195-217.
37. Herrero MT, Perez-Otano I, Oset C, Kastner A, Hirsch EC, Agid Y, et al. GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 1993; 56: 965-72.
38. Bianchi R Janigro D, Milan F, Giudici G, Gorio A. In vivo treatment with GM1 prevents the rapid decay of ATPase activities and mitochondrial damage in hippocampal slices. Brain Res 1986; 364: 400-4.
39. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 2006; 122: 245-57.
40. Ledeen RW, Wu G Ganglioside function in calcium homeostasis and signaling. Neurochem Res 2002; 27: 637-47.
41. Ledeen RW, Wu G. Gangliosides of the nuclear membrane: a crucial locus of cytoprotective modulation. J Cell Biochem 2006; 97: 893-903.
42. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-8.